Chemomab Therapeutics (CMMB) Research & Development (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Research & Development came in at $1.1 million in Q4 2025, down 54.67% YoY from $2.4 million in Q4 2024, and up 13.85% on a QoQ basis from $960000.0 in Q3 2025.
Chemomab Therapeutics (CMMB) Research & Development (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Research & Development data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Research & Development fell 54.67% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.8 million (down 48.5% YoY) and the FY2025 annual result came in at $5.8 million, down 48.5% from the prior year.
- Research & Development climbed to $1.1 million in Q4 2025, from $960000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $6.9 million in Q1 2023 to a low of $960000.0 in Q3 2025.
- A 5-year average of $2.9 million and a median of $2.8 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 264.69% — and 2025, when it tumbled 66.15%.
- Tracing CMMB's Research & Development over 5 years: stood at $2.4 million in 2021, then surged by 147.38% to $5.9 million in 2022, then tumbled by 47.46% to $3.1 million in 2023, then fell by 22.15% to $2.4 million in 2024, then sank by 54.67% to $1.1 million in 2025.
- The last three Research & Development figures came in at $1.1 million (Q4 2025), $960000.0 (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 960,000.00 |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Dec 31, 2024 | 2.41 Mn |
| Sep 30, 2024 | 2.84 Mn |
| Jun 30, 2024 | 2.93 Mn |
| Mar 31, 2024 | 3.15 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 3.38 Mn |
| Jun 30, 2023 | 5.02 Mn |
| Mar 31, 2023 | 6.89 Mn |
| Dec 31, 2022 | 5.90 Mn |
| Sep 30, 2022 | 5.42 Mn |
| Jun 30, 2022 | 2.91 Mn |
| Mar 31, 2022 | 2.75 Mn |
| Dec 31, 2021 | 2.38 Mn |
| Sep 30, 2021 | 1.49 Mn |
| Jun 30, 2021 | 1.31 Mn |
| Mar 31, 2021 | 1.16 Mn |